Each one in plain English, with the numbers worked through for a shareholder.
5 Sept 2023other material event▼ BadMajor
The board says that as of August 31, 2023 the parties could not complete certain material objectives on time, so it voided the Artesian Valley Farms and JRD Ventures contracts. This covers the Guffey membership purchase agreement, the $500,000 and $2.9M notes, the DeAngelis exchange agreement, the $399,000 note, and the Lower Ranch lease. It says it is releasing its claim to assets held in escrow and cancelling contingent debt obligations, intending to sign new agreements with the parties later. This reverses the 2021-22 acquisitions that the May 2022 release described as completed. It resolves the note-repayment and lease thread by cancelling them. The filing does not say what happens to the shares issued in November 2021 or whether the Rhino Biotech, Inc. (Ohio) deal is affected. It says the company aims to file its 20-F and resume trading on the open market before year end.
A May 4, 2022 press release announced completion of the acquisitions of Artesian Valley Farms, LLC and Rhino Biotech, Inc. (Ohio), first disclosed in the March 2022 filing. It describes the business as plant and fungi-derived nutraceuticals and biopharmaceuticals, with a 27,000 sq ft cultivation facility on 13 acres in Durango, Colorado. The release's deal values differ from the March filing: Artesian $14.5M in stock plus $3.4M financing, JRD $3.1M in stock, Rhino Inc. $10M in shares, versus $17.9M, $2.1M and a share-only deal earlier. The filing also notes a May 4, 2022 investor showcase presentation. The release answers the open question about what the business is. It does not give a share count or say who controls the company.
A short filing says Robert Hesse resigned as interim Chairman effective August 19, 2021, with no disagreement with the company. That date is a week before the January 2022 filing says he was appointed a director (August 26, 2021) and that he has been Chairman since August 2021, so the filings do not fully line up. The filing does not explain this.
Following the acquisitions, the company changed its industry code from 1311 (Crude Petroleum and Natural Gas) to 2833 (Medicinal Chemicals and Botanical Products) and updated its principal office address. This formally moves the company out of the oil and gas category. The filing gives no other new facts.
The company disclosed deals dated September 3, 2021. It bought Artesian Valley Farm, LLC (Colorado) for $17.9M: a $500,000 note at 6% due October 31, 2023, a $2.9M secured note at 3% due September 3, 2022, and 750,000,000 shares. It bought JRD Ventures LLC for $2.1M: a $399,000 note at 12% due July 29, 2022 and 85,050,000 shares. It bought Rhino Biotech, Inc. (Ohio) for 500,000,000 shares. All shares were issued November 3, 2021, 1,335,050,000 in total against the 34,548,368 shares last reported outstanding (September 2019). It also signed a ten-year lease from December 1, 2021 on about 27,000 sq ft in Durango, Colorado at $175,000 a month. The ticker changed from EUENF to RBRXF on February 17, 2022. The filing is also marked as a change in control. For existing shareholders this is very heavy dilution and a complete break from the Azerbaijan oil search.
Filed January 20, 2022 (cover says 'January 2021'), this reports a board and name overhaul. Stephen Kenwood resigned as director and Graham Crabtree as CFO on August 20, 2021. Robert Hesse (Chairman) and Marilyn Roosevelt were appointed directors on August 26, 2021, and Nicholas Baxter resigned as director the same day. The company raised its authorized common shares to 2,500,000,000 on August 10, 2021 (from the 100,000,000 in earlier filings) and became Rhino Biotech Limited on September 15, 2021. The long-time Eurasia management is gone; the filing says the resignations were not due to disagreements.
Notice of the November 4, 2019 annual meeting, with a September 30, 2019 record date and two director nominees. Shareholders are asked to ratify Davidson & Company LLP as 2019 auditor, ratify acts since January 1, 2017, and approve a 'Reverse Stock Split' and a 'Share Capital Alteration'. The details of the last two are in the proxy statement, whose text is not provided here, so their terms are unknown. Shares outstanding were 34,548,368 of 100,000,000 authorized as of September 30, 2019. The two new capital items are a first in this series of notices.
Directors Roger Thomas and Gerald Tuskey resigned from the board, announced December 13, 2018. The filing gives no reason and names no replacements. Nicholas Baxter signs the filing as director. Tuskey had signed most earlier filings and was the CFO and director in the prior context, so the board looks thinner (inference). The filing does not say whether Tuskey also left his CFO role.
A June 2017 Form 6-K that only lists annual meeting materials (notice, information circular, proxy) as exhibits. The exhibit text is not included, so no meeting date or agenda can be stated. The May 2017 announcement said Davidson & Company would be put to shareholders at the next annual meeting; inferred to be this one, but unconfirmed.
Eurasia announced a new auditor, effective February 1, 2017, replacing Anton & Chia LLP. Anton & Chia resigned after Eurasia refused to increase the fees under a three-year fixed-fee arrangement. The board will ask shareholders at the next annual meeting to appoint Davidson & Company, LLP. The board and audit committee said they know of no matters about the change that shareholders should be told about. This ends the Peterson Sullivan-era auditor line shown in earlier meeting notices.
A June 2016 Form 6-K that only lists annual meeting materials (notice, information circular, proxy) as exhibits. The exhibit text is not included, so no meeting date or agenda can be stated. This appears to be routine annual meeting paperwork.
A Form 6-K that attaches an April 27, 2016 announcement 'regarding change of auditor'. The announcement text is not included, so who was replaced and why cannot be stated. The 2017 auditor-change filing shows Anton & Chia LLP was the auditor by then.
A June 2015 Form 6-K that only lists annual meeting materials (notice, information circular, proxy) as exhibits. The exhibit text is not included, so no meeting date or agenda can be stated. This appears to be routine annual meeting paperwork.
Notice of the 2014 annual meeting, to be held July 9, 2014 in Anguilla, with a May 28, 2014 record date. The agenda is the usual one: elect directors, ratify Peterson Sullivan LLP as 2014 auditor, and ratify acts since January 1, 2013. Shares outstanding are still 34,548,368, the same as a year earlier. This is routine and shows no new business.
Notice of the 2013 annual meeting, to be held July 11, 2013 in Anguilla. Shareholders of record on May 31, 2013 vote on electing directors, ratifying Peterson Sullivan LLP as auditor for 2013, and ratifying the directors' and officers' acts since January 1, 2012. The circular shows 34,548,368 shares outstanding as of June 18, 2013, up from the 2012 holdings after the April 2012 salary-in-shares issues. This is routine annual paperwork and announces no project.
A June 2012 Form 6-K that only lists annual general meeting materials (notice, information circular, proxy) as exhibits. The exhibit text is not included, so no meeting date or agenda can be stated; this appears to be routine annual meeting paperwork.
Nicholas W. Baxter filed a Schedule 13D/A after acquiring 5,000,000 shares on April 17, 2012 at a deemed $0.05 each in lieu of accrued salary. This lifted his holding to 7,573,364 shares, or 21.92% of the company.
Graham Crabtree filed a Schedule 13D/A after acquiring 3,600,000 shares on April 17, 2012 at a deemed $0.05 each in lieu of accrued salary. This lifted his holding to 6,788,333 shares, or 19.65% of the company.
A cover-page-only Form 6-K that attaches a Jan 13, 2012 news release. The release text is not included in the filing provided, so its content cannot be summarised.
A June 2011 shareholder mailing says management is working with Commonwealth and Arawak under the Feb 2010 Participation Agreement to identify and ultimately negotiate an interest in an upstream project in Azerbaijan, and that this will be the main focus through 2011. No project is announced. It also gives notice of a July 14, 2011 annual meeting (directors, auditor Peterson Sullivan LLP, ratification of acts since Jan 1, 2010).
A June 2010 shareholder mailing reports that on Feb 10, 2010 Eurasia, Commonwealth, Arawak and Baxter signed a Participation Agreement that finally resolved the litigation running since 2006 and sets terms for the parties to cooperate in seeking an upstream oil and gas project in Azerbaijan. Commonwealth has reimbursed Eurasia for 51% of its agreed third-party costs to date. The mailing also gives notice of a July 16, 2010 annual meeting (director elections, auditor ratification, ratification of acts since Jan 1, 2009). This resolves the lawsuit thread and turns the former opponents into partners in a joint search for a project; no project is secured.
A cover-page-only Form 6-K that attaches a March 17, 2010 news release. The release text is not included in the filing provided, so its content cannot be summarised.
A cover-page-only Form 6-K that attaches a Feb 17, 2010 news release. The release text is not included in the filing provided, so its content cannot be summarised.